Scilex Holding Announces FDA Final Approval To Precision Dosing For GLOPERBA Label
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company has received FDA approval for precision dosing on the GLOPERBA label, a liquid oral version of colchicine for gout treatment. This approval targets a significant unmet need in the gout treatment market, projected to reach $2 billion by 2028.
August 29, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex Holding Company received FDA approval for precision dosing on GLOPERBA, a liquid oral colchicine for gout. This positions Scilex to address a growing market need, potentially boosting its market share and revenues.
The FDA approval for precision dosing on GLOPERBA allows Scilex to cater to a significant portion of the gout market, especially patients with comorbid conditions requiring dose adjustments. This approval could enhance Scilex's market position and revenue potential in a market projected to grow to $2 billion by 2028.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100